Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Sihuan Pharmaceutical Holdings Group Cash Conversion Cycle Related Terms
Sihuan Pharmaceutical Holdings Group Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group Cash Conversion Cycle Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Cash Conversion Cycle falls into.
Sihuan Pharmaceutical Holdings Group Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group (SHPHF) has a Cash Conversion Cycle of 191.46 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors.
Is Sihuan Pharmaceutical Holdings Group's Cash Conversion Cycle too high?
Sihuan Pharmaceutical Holdings Group's current Cash Conversion Cycle is 191.46. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. Sihuan Pharmaceutical Holdings Group's value of 191.46 is 31.3% above this industry median. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Cash Conversion Cycle compare to ZTS?
Sihuan Pharmaceutical Holdings Group's Cash Conversion Cycle of 191.46 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. Sihuan Pharmaceutical Holdings Group's value of 191.46 is 31.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current Cash Conversion Cycle of 191.46 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current Cash Conversion Cycle is 191.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.18, compared to a current price of $0.13 — trading 27.9% below its estimated fair value. The current Cash Conversion Cycle is 191.46 and 31.3% above the Drug Manufacturers industry median of 145.82. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current Cash Conversion Cycle is 191.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.13 is trading 27.9% below its estimated GF Value™ of $0.18.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
Cash Conversion Cycle: 191.46
GF Value™: $0.18 vs. price of $0.13 (27.9% below fair value)
Industry Position: 31.3% above the Drug Manufacturers median
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
51GF Score
Get the complete analysis for SHPHF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
